Premium
c ‐ erbB ‐ 2 oncogene expression in ovarian cancer
Author(s) -
Haldane J. S.,
Hird V.,
Hughes C. M.,
Gullick W. J.
Publication year - 1990
Publication title -
the journal of pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.964
H-Index - 184
eISSN - 1096-9896
pISSN - 0022-3417
DOI - 10.1002/path.1711620309
Subject(s) - polyclonal antibodies , staining , cytoplasm , immunohistochemistry , ovary , oncogene , biology , pathology , cancer , antibody , microbiology and biotechnology , medicine , endocrinology , immunology , cell cycle
One hundred and four common epithelial malignancies of the ovary were stained for c ‐ erbB ‐ 2 using an affinity‐purified polyclonal antibody 21N. Twenty‐three out of 104 (22·1 per cent) showed cytoplasmic staining alone. Nine out of 104 (8·7 per cent) showed both membrane and cytoplasmic staining. In a multivariate Cox analysis with other known risk factors the relative risk for cytoplasmic staining alone was 1·456 (χ 2 =1·71, P >0·1) and for membrane and cytoplasmic staining 0·316 (χ 2 =7·95, P < 0·005). These results do not support an adverse prognostic effect of c ‐ erbB ‐ 2 in our patients.